However, our observation that the H3K9me2 blocks can be suppressed by pharmacological inhibition of the histone methyltransferase G9a/GLP (Fig 7) suggests that limiting H3K9me2 spreading in AML may prevent the reactivation of oncogenes resulting from the secondary AML-specific gene mutations and chromosomal translocations. This evidence concerns the gene PRDM9 and acute myeloid leukemia.